Agios Pharmaceuticals, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; unaudited. Agios is a rare-disease biopharmaceutical company. Its marketed product is PYRUKYND (mitapivat), approved for adults with pyruvate kinase (PK) deficiency; its pipeline includes programs in thalassemia, sickle cell disease (SCD), pediatric PK deficiency, lower-risk myelodysplastic syndrome (LR MDS), phenylketonuria (PKU), and polycythemia vera (PV).
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Product revenue | $8.2 million | $5.6 million; up $2.6 million (46%), attributed to PYRUKYND sales |
| Cost of sales | $0.6 million | $0.6 million |
| Research and development | $68.6 million | $67.3 million |
| Selling, general and administrative | $31.0 million | $28.4 million |
| Total operating expenses | $100.3 million | $96.2 million |
| Operating loss | $92.1 million | $90.6 million |
| Interest income, net | $8.9 million | $8.1 million |
| Net loss | $81.5 million; $1.45 per share | $81.0 million; $1.47 per share |
| Operating cash flow | $(99.9) million | $(95.2) million |
Gross profit was approximately $7.6 million, or 92% of revenue, calculated from reported revenue and cost of sales. The company reported no debt; it did report operating lease liabilities of $68.3 million, including current and non-current portions. Total assets were $849.7 million and stockholders’ equity was $743.9 million at quarter-end.
Cash, cash equivalents, and marketable securities totaled $714.3 million at March 31, 2024, down from $806.4 million at December 31, 2023. Cash and cash equivalents alone were $118.8 million. Investing activities provided $124.6 million, primarily because maturities and sales of marketable securities exceeded purchases; financing activities provided $5.9 million from employee equity plans. Management expects available liquidity to fund operations for at least 12 months and states it expects funding through several value-creating milestones and at least into 2026, including anticipated product revenue, interest income, and the potential vorasidenib milestone.
Material changes and business developments
- Revenue increased 46% year over year, while operating expenses rose 4.2%. Net loss increased by $0.5 million despite higher revenue and interest income.
- R&D rose $1.3 million: higher PYRUKYND process-development spending was partly offset by lower AG-946 costs and lower indirect expenses. SG&A increased $2.6 million, primarily due to commercial preparation for potential thalassemia approval.
- PYRUKYND phase 3 ENERGIZE study in non-transfusion-dependent thalassemia met its primary endpoint: hemoglobin response was 42.3% with mitapivat versus 1.6% with placebo (p<0.0001); both key secondary endpoints were also statistically significant. Agios aims to submit an FDA NDA for thalassemia by year-end 2024.
- In ENERGIZE-T, a phase 3 study in transfusion-dependent thalassemia, enrollment was complete; topline results were expected in Q2 2024.
- The phase 2 portion of the RISE UP SCD study previously met its hemoglobin-response endpoint. The phase 3 portion began enrollment; the company expected to complete enrollment by year-end 2024 and announce topline results in 2025.
- ACTIVATE-kidsT enrollment was complete, with topline results expected by mid-2024. ACTIVATE-kids was enrolling, with enrollment expected to finish by mid-2024 and topline results in 2025.
- AG-946’s phase 2a LR MDS study reported proof-of-concept results in 2023; Agios planned to assess the results and expected to initiate a higher-dose phase 2b study in mid-2024. AG-181 entered a phase 1 healthy-volunteer trial in Q1 2024.
Outlook, risks, and contingencies
Management expects continued significant expenses and net losses as it advances clinical development and commercialization. Future costs and timelines depend on trial outcomes, enrollment, regulatory review, manufacturing, reimbursement, and commercial uptake. The filing does not provide a clear numerical full-year revenue or earnings forecast.
Agios retains a potential $200 million payment from Servier if vorasidenib receives qualifying FDA approval before January 1, 2027, plus a 15% royalty on U.S. vorasidenib net sales after launch. Servier’s NDA received FDA priority review; the PDUFA action date was August 20, 2024. The milestone and royalties are contingent, and their receipt or amount is not assured. Agios has no other committed external funding source. Its Alnylam license includes up to $130 million in potential development and regulatory milestones, as well as sales milestones and tiered royalties.
Principal risks include ongoing losses and cash-burn uncertainty; dependence on PYRUKYND commercialization and successful clinical and regulatory outcomes; competition, reimbursement and pricing pressure; reliance on third-party manufacturers, CROs and suppliers; clinical-trial enrollment and execution risks; intellectual-property and product-liability exposure; and potential need for additional capital, which could dilute shareholders or constrain operations. Management reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Key facts for investors to verify
- Whether PYRUKYND revenue growth translates into sustained commercial adoption, reimbursement, and improving operating leverage.
- Subsequent results and regulatory progress for ENERGIZE-T, ACTIVATE-kidsT, the planned thalassemia NDA, and the SCD phase 3 trial.
- FDA’s decision on vorasidenib and whether the qualifying approval conditions for Agios’s contingent $200 million milestone are met.
- Actual cash use versus management’s stated funding horizon through at least 2026, particularly as clinical and commercial spending evolves.
- Potential milestone, sales milestone, and royalty obligations under the Alnylam agreement, and the related development costs.